Biotech entity
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Aquestive Therapeutics, Inc., the most common co-covered peer. That works out to roughly 1.6 stories per week across a 9-day span.
Last mentioned: Mar 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Aquestive Therapeutics, Inc., the most common co-covered peer. That works out to roughly 1.6 stories per week across a 9-day span. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. Each story carries 3.5 original sources on average, compared with 3.8 for the broader beat in this window. This profile follows 2 Biotech stories mentioning Pomerantz Law Firm across the period from March 5, 2026 to March 13, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 133 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pomerantz Law Firm. Shared-story counts are live from our verified record — not editorial picks.
Motion to Dismiss Phase
Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
Lead Plaintiff Deadline (Est.)
Typical 60-day window for investors to petition the court to lead the consolidated class action.
Investor Alerts Issued
Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.
Pomerantz Law Firm has issued a formal reminder to Aquestive Therapeutics (AQST) investors regarding an ongoing class action lawsuit following a period of financial underperformance. The litigation coincides with a recent quarterly earnings miss and notable insider selling, creating a challenging regulatory and legal environment for the biotech firm.
Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Pomerantz Law Firm is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
